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PROPHYLAXIS FOR HERPETIC VIRUSES POST AUTOLOGOUS STEM CELL
TRANSPLANTS: A RETROSPECTIVE REVIEW AT A REGIONAL TRANS-
PLANT CENTER
Bohnenblust, E.1, Ramey, S.1, Schisler, N.1, Thompson, L.1,
Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2 1Furman Univer-
sity, Greenville, SC; 2Cancer Centers of the Carolinas, Greenville, SC
Following hematopoietic stem cell transplantation as a treatment
for hematological disease, prophylactic care for herpetic infections in
immunocompromised patients is essential. Acyclovir is a widely pre-
scribed anti-viral medication that can reduce the risk of HSV, CMV,
EBV, and VZV reactivation in post-transplant patients. The benefits
of acyclovir include low cost and low toxicity. However, the usage,
dosage, and duration of acyclovir treatment vary among treatment
centers. To evaluate the efficacy of one acyclovir prophylaxis proto-
col, we performed a retrospective review from 2002–2007 of all pa-
tients (n 5 150) who underwent single or tandem autologous
peripheral blood stem cell transplantations at the Cancer Centers
of the Carolinas (CCC). The CCC’s standard operating procedure
suggests that patients receive 400 mg of acyclovir BID three times
per week following transplantation until the patient’s CD4 count
reaches the 400 cells/mliter threshold. CD4 count testing began at
200 days with subsequent tests every 100 days until patients reached
threshold. Only 19% of patients were tested to threshold in this
study. Acyclovir prophylaxis was terminated prior to threshold in
30% of patients. CD4 counts performed at 200 days post transplant,
had a median value of 232 cells/mliter. Within the 28 patient cadre
that were monitored for CD4 counts, 53% reached threshold within
199 days, 67%within 299 days, and 82%within 399 days post-trans-
plantation. The remaining 17% reached threshold 400 or more days
post-transplantation. These results suggest reassessment of the CD4
count threshold at critical time junctures in the reconstitution of the
immune system is necessary to avoid indefinite acyclovir therapy. A
myriad of issues influence patient compliance and provider response
to results. Some of these factors include patient non-compliance, in-
complete testing, results not available for office visits andmanual sys-
tems for ordering and analysis. The conclusion of this study focuses
on areas for process improvement.With the development of a FACT
compliant EMR (Electronic Medical Record), our center will create
transplant specific triggers to assure appointments are made and re-
sults obtained for provider assessment. Additional data pointsmay be
developed to track HSV, VZV, CMV and EBV antibody status as
well as the incidence of relevant viral infections and concomitant an-
tiviral therapy. Computerized results will allow on-going tracking,
follow-up and analysis.432
SYMPTOMS AND PERSONALITY TRAITS IN PATIENTSWITH HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
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Song, B.E.2, Kim, K.S.1 1St. Mary’s Hospital, Seoul, Korea; 2Catholic
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The purpose of this study is to investigate the personality of pa-
tients with HSCT, to identify the symptom experience shown by pe-
riods of transplantation, and to present basic database in order to
formulate more effective, optimum nursing interventions for
HSCT. The subjects of this study were 100 patients who were 18
years of age and older and underwent HSCT at the HSCT center
in S Hospital of C University located in Seoul. The data were col-
lected between October 1, 2007 and August 15, 2008. The personal-
ity trait was measured once at the next day of hospitalization for
transplantation, by using of the shortened version of NEO-PI-R,
which was translated and adapted in Korean. The symptom experi-
ence was investigated three times ‘pre-transplant stage(T1)’, ‘trans-
plant stage(T2)’ and ‘post-transplant stage(T3)’ of HSCT for each
subject, by using of a tool translated and adapted in Korean from
Symptom Occurrence(Frequency), Intensity & Distress-Stem Cell
Transplantation (SFID–SCT). The results of this study are as fol-lows; Over 80% of the patients showed changes in taste, loss of ap-
petite, mouth dryness, fatigue, diarrhea, nausea, insomnia, and
mouth sores in the period of T2. Changes in taste and loss of appetite
were highest in the scores of symptom occurance(SO), while changes
in taste were highest in the scores of symptom distress(SD). As for
the personality factors of the patients withHSCT, the score of agree-
ableness was highest. There was no significant difference in person-
ality traits according to the types of transplantation and disorders.
Among the five personality factors of the patients with HSCT, neu-
roticism and extraversion affected the symptoms. Neuroticism as
a factor affected almost all the periods of transplantation for the
symptom intensity(SI) and SD, except the SI of T3. Extraversion af-
fected all the periods of transplantation for the SI and SD. Conclu-
sively, the SO, SI and SD were highest in T2, and the neuroticism
and extraversion among the personality traits of the patients with
HSCT affected the symptoms. Therefore, it is necessary to develop
nursing interventions appropriate for patients who had higher neu-
roticism and extraversion. As with the SO, SI and SD according to
the transplantation periods in patients with HSCT, changes in taste
and loss of appetite were highest all the periods of transplantation. It
is offered that further development and evaluation research of effec-
tive diet programs for patients with HSCT are necessary.433
ENHANCING THE SAFETY OF HIGH RISK MEDICATION ADMINISTRATION
ON AN INPATIENT STEM CELL TRANSPLANT UNIT
Johnson, M., White, A., Jacob, R., Johnston, P. The University of Md
Anderson Cancer Center, Houston, TX
Background: Medication administration errors are an increasing
concern in health care. High dose chemotherapy, biologicmodifying
agents, and medications used in the prevention and treatment of
GVHD account for a portion of these errors. The effects of these
medication errors can be lethal when they are administered incor-
rectly. With the increasing use of agency and float pool staff, there
may be nurses administering these agents who are not familiar
with the correct procedure for administration or the side effects as-
sociatedwith them.The Joint Commission has identifiedmedication
safety as one of its 2009 National Patient Safety goals. Nine patient
safety solutions have been previously identified by the International
Steering Committee. These solutions are to be used as a guide in
evaluating and re-designing delivery of care to focus on prevention
of medication errors and safe medication administration. In imple-
menting these solutions into our model of care for our 52 bed impa-
tient Stem Cell Transplant and Cellular Therapy Unit, we have
identified the need for an additional measure to decrease the risk
of medication administration errors with those particular high risk
medications.
Interventions: A tool was developed to aid in the administration
of chemotherapy, biologic modifying agents, and medications used
in the prevention and treatment of GVHD. These tools included
the name of the drug, the tubing and filter to be used, the vital
sign schedule, the side effects, and any miscellaneous information
that needed to be included for each specific medication. The tool
was then placed in each of the chemotherapy preparation areas where
the nurses would be able to see and access the information easily.
Results: An evaluation tool was administered to the nurses on
SCTCT unit to determine if the tool was effectively making it easier
to access the correct information about the medications that they
were administering.
Recommendations:The creation of a chemotherapy/medication
chart on our inpatient SCTCT unit has assisted in decreasing the
number of medication errors as well as increasing the awareness of
nursing staff in regards to safe administration of these agents.434
UTILITY OF INSUFLONe CATHETERS AFTER PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION: TAKING THE PAIN OUT OF SUBCU-
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